What is the role of the CxBladder assay in the diagnosis of bladder cancer?

Updated: Nov 01, 2018
  • Author: Gary David Steinberg, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print


CxBladder (PacificEdge, Dunedin, New Zealand) is a recently released urine-based assay consisting of 5 mRNA markers, CDC2, HOXA13, MDK, IGFBP5, and CXCR5. [33] The addition of CXCR5, or a mediator of neutrophil migration to sites of inflammation, allows the reduction of false positives secondary to the presence of acute or chronic inflammation. The sensitivity of this assay is superior to that of NMP-22 and cytology, at 83%, with a specificity of 85%. Interestingly, the specificity for high-grade tumors was 97% while the specificity for low-grade tumors was 69%. This offers a potential adjunct to cystoscopy for the diagnosis of urothelial carcinoma.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!